文献速递主动脉疾病

血管腔内动脉瘤修复术中预防性栓塞瘤囊或主动脉侧支:随机对照试验的荟萃分析与试验序贯分析

Pre-Emptive Embolization of the Aneurysm Sac or Aortic Side Branches in Endovascular Aneurysm Repair: Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
PubMed 文献 · Ann Vasc Surg · 2022-12-06

本研究纳入4项随机对照试验,比较血管腔内动脉瘤修复术(EVAR)中联合与不联合预防性栓塞的结局。预防性栓塞组II型内漏(OR 0.45,95%CI 0.26-0.78)和瘤囊扩张(OR 0.19,95%CI 0.07-0.52)的 odds 显著降低,但动脉瘤相关死亡、全因死亡、动脉瘤破裂、II型内漏相关再干预、手术时间和透视时间均无显著差异。所有结局偏倚风险高,证据确定性极低(II型内漏为低),结论认为预防性栓塞在EVAR中未 confer 临床获益。

要点

  • 预防性栓塞显著降低II型内漏(OR 0.45,95%CI 0.26-0.78)和瘤囊扩张(OR 0.19,95%CI 0.07-0.52)的 odds。
  • 动脉瘤相关死亡、全因死亡、破裂、II型内漏相关再干预、手术时间和透视时间均无显著差异。
  • 所有结局偏倚风险高,证据确定性极低(II型内漏为低),结论认为无临床获益。

核心结论

  • 有限且低确定性的数据提示,在EVAR中预防性栓塞未 confer 临床获益。

研究设计与样本

  • 系统综述与荟萃分析,遵循PRISMA 2020并预注册方案,检索MEDLINE、Embase和CENTRAL,纳入比较EVAR联合与不联合栓塞的随机对照试验,共4项。
  • 二分类结局采用Mantel-Haenszel法计算OR或RD及95%CI,连续结局采用逆方差法计算MD及95%CI,采用GRADE框架评价证据确定性,Cochrane偏倚风险评估工具版本2评估偏倚风险,试验序贯分析设定α=5%、把握度=80%。

主要发现

  • 预防性栓塞组与非栓塞组相比,II型内漏的 odds 显著降低(OR 0.45,95%CI 0.26-0.78),瘤囊扩张的 odds 显著降低(OR 0.19,95%CI 0.07-0.52)。
  • 动脉瘤相关死亡无显著差异(RD 0.00,95%CI -0.03至0.03),全因死亡无显著差异(OR 1.85,95%CI 0.42-8.13),动脉瘤破裂无显著差异(RD 0.00,95%CI -0.03至0.03)。
  • II型内漏相关再干预无显著差异(RD -0.07,95%CI -0.21至0.06),手术时间无显著差异(MD 20.12,95%CI -11.54至51.77),透视时间无显著差异(MD 11.17,95%CI -11.22至33.56)。

关键数值与推荐

  • II型内漏:OR 0.45(95%CI 0.26-0.78),预防性栓塞组 odds 显著低于非栓塞组。
  • 瘤囊扩张:OR 0.19(95%CI 0.07-0.52),预防性栓塞组 odds 显著低于非栓塞组。
  • 全因死亡:OR 1.85(95%CI 0.42-8.13),无显著差异。
  • 动脉瘤相关死亡:RD 0.00(95%CI -0.03至0.03),无显著差异。
  • II型内漏相关再干预:RD -0.07(95%CI -0.21至0.06),无显著差异。

临床怎么用

  • 原文结论认为预防性栓塞在EVAR中未 confer 临床获益,未据此给出推荐。

局限性

  • 所有结局的偏倚风险均为高。
  • 除II型内漏(证据确定性为低)外,所有结局的证据确定性均为极低。
  • 试验序贯分析显示全因死亡和II型内漏相关再干预的结果为不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate outcomes of pre-emptive embolization of the aneurysm sac or aortic side branches in endovascular aneurysm repair (EVAR). METHODS: The review was reported as per Preferred Reporting Items for Systematic reviews and Meta-Analyses 2020 with a preregistered protocol. Bibliographic sources (MEDLINE, Embase, and CENTRAL) were searched using subject headings and free text terms. Randomized controlled trials comparing EVAR with versus without embolization were included. Pooled estimates of dichotomous outcomes were calculated using odds ratio (OR) or risk difference (RD) and 95% confidence interval (CI) applying the Mantel-Haenszel method. Continuous outcomes were summarized using mean difference (MD) and 95% CI applying the inverse variance method. The certainty of evidence was appraised with the Grading of Recommendations Assessment, Development, and Evaluation framework. Version 2 of the Cochrane tool was used to assess the risk of bias. Trial sequential analysis assumed alpha = 5% and power = 80%. RESULTS: Four randomized controlled trials were included. No significant difference was found in aneurysm-related mortality (RD 0.00, 95% CI -0.03 to 0.03), overall mortality (OR 1.85, 95% CI 0.42-8.13), aneurysm rupture (RD 0.00, 95% CI -0.03 to 0.03), type II endoleak-related reintervention (RD -0.07, 95% CI -0.21 to 0.06), procedure time (MD 20.12, 95% CI -11.54 to 51.77), or fluoroscopy time (MD 11.17, 95% CI -11.22 to 33.56). Patients with pre-emptive embolization had significantly lower odds of type II endoleak (OR 0.45, 95% CI 0.26-0.78) and sac expansion (OR 0.19, 95% CI 0.07-0.52). The risk of bias was high for all outcomes. The certainty of evidence was very low for all outcomes, except for type II endoleak, for which it was low. Trial sequential analysis showed an inconclusive result for overall mortality and type II endoleak-related reintervention but confirmed the advantage of embolization in reducing type II endoleak and sac expansion. CONCLUSIONS: Limited, low certainty data suggest pre-emptive embolization confers no clinical benefits in EVAR.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kontopodis N, Galanakis N, Kiparakis M, et al. Pre-Emptive Embolization of the Aneurysm Sac or Aortic Side Branches in Endovascular Aneurysm Repair: Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Ann Vasc Surg. 2022. PMID: 36494004. doi:10.1016/j.avsg.2022.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。